Musculoskeletal ultrasound to assess therapeutic effects of novel antirheumatic therapies in Psoriatic Arthritis

Completed

• Conditions: inflammatory arthritis; psoriatic arthritis; 10023213; 10014982

• Registration Number: NL-OMON46720
• Lead Sponsor: Reade

Brief Summary

Trial ended prematurely

Detailed Description

Not available

Study Timeline

• Study Completion: 2021-04-21
• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 4

Inclusion Criteria

- 18 years or older
- Active psoriatic arthritis, defined as *2 swollen and *2 tender joints
- Starting with apremilast, secukinumab or anti-TNF therapy

Exclusion Criteria

- Other active concomitant musculoskeletal disease

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main outcomes of the study are the early ultrasound findings (baseline.<br /><br>week 2 and week 4) and the clinical therapeutic response to apremilast and<br /><br>secukinumab at 24 weeks</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcomes of the study are ultrasound findings and clinical<br /><br>assessments at all time points.</p><br>